Company intelligence / Profile preview

Lateral Pharma

Melbourne, Victoria, Australialateral-pharma.com ↗

Ownership: Private
Employees: ~6
Development stage: Phase 2

Overview

Lateral Pharma’s lead compound LAT8881 is an orally available small molecule/peptide with extensive human safety data. It has completed preclinical studies showing efficacy in animal models of neuropathic pain and respiratory disease. The company is conducting or planning Phase 1/2 clinical trials for neuropathic pain indications. Additional peptide candidates are in preclinical development for both pain and respiratory diseases[1][4].

Therapeutic areas: PulmonologyEndocrinologyNeurologyInfectious Diseases
Modalities: Small moleculePeptides
Industry: Biotech

Drug pipeline

2 assets

LAT8881

1 more asset in the full pipeline.

Request access →

Partnerships

NIH Preclinical Screening Platform for Pain collaboration on two lead peptides

Beyond the preview

Go deeper on Lateral Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lateral Pharma.

Explore the full profile